impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Full Papers

 

The assessment of the drug retention rate of secukinumab in patients with psoriatic arthritis in a real-life multicentre cohort

1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21

 

  1. Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy. piero.ruscitti@univaq.it, pieroruscitti@live.com
  2. University della Campania Luigi Vanvitelli, School of Medicine and Surgery, Department of Precision Medicine, Naples, Italy.
  3. Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy.
  4. Medical Clinic, SS. Annunziata Hospital of Chieti, Department of Medicine and Science of Aging, G. D'Annunzio University of Chieti-Pescara, Chieti, Italy.
  5. Rheumatology Unit, Santo Spirito Hospital, Pescara, Italy.
  6. University della Campania Luigi Vanvitelli, School of Medicine and Surgery, Department of Precision Medicine, Naples, Italy.
  7. University della Campania Luigi Vanvitelli, School of Medicine and Surgery, Department of Precision Medicine, Naples, Italy.
  8. University della Campania Luigi Vanvitelli, School of Medicine and Surgery, Department of Precision Medicine, Naples, Italy.
  9. University della Campania Luigi Vanvitelli, School of Medicine and Surgery, Department of Precision Medicine, Naples, Italy.
  10. University della Campania Luigi Vanvitelli, School of Medicine and Surgery, Department of Precision Medicine, Naples, Italy.
  11. Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy.
  12. Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy.
  13. Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy.
  14. Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Campus Bio-Medico, Rome; and Rheumatology and Clinical Immunology, Department of Medicine, University of Rome Campus Biomedico, School of Medicine, Rome, Italy.
  15. Rheumatology Unit, Santo Spirito Hospital, Pescara, Italy.
  16. Rheumatology Unit, Santo Spirito Hospital, Pescara, Italy.
  17. Medical Clinic, SS. Annunziata Hospital of Chieti, Department of Medicine and Science of Aging, G. D'Annunzio University of Chieti-Pescara, Chieti, Italy.
  18. Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy.
  19. Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Campus Bio-Medico, Rome; and Rheumatology and Clinical Immunology, Department of Medicine, University of Rome Campus Biomedico, School of Medicine, Rome, Italy.
  20. University della Campania Luigi Vanvitelli, School of Medicine and Surgery, Department of Precision Medicine, Naples, Italy.
  21. Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Italy.

CER16494
2024 Vol.42, N°1
PI 0069, PF 0076
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 37497733 [PubMed]

Received: 03/01/2023
Accepted : 19/06/2023
In Press: 24/07/2023
Published: 24/01/2024

Abstract

OBJECTIVES:
We aimed to evaluate the drug retention rate (DRR) of secukinumab, an anti-IL-17A monoclonal antibody, in patients with psoriatic arthritis (PsA) in a real-life cohort, and to assess the impact of comorbidities and patient clinical characteristics on the DRR of secukinumab.
METHODS:
A retrospective study of prospective followed-up patients was performed to evaluate the DRR of secukinumab on patients with PsA attending the recruiting centres between January 2016 and June 2022.
RESULTS:
In 207 patients with PsA, a 60-month DRR of secukinumab of 57.0% was estimated (mean time of administration of 21.5±17.1 months). Male gender, age ≥65 years, disease duration ≥5 years and ≥10 years did not influence the DRR of secukinumab. The presence of comorbidities, considering any concomitant disorder, did not affect the DRR of secukinumab. In patients with cardiometabolic multimorbidity, a trend toward a better DRR of secukinumab was recorded. In fact, patients with high blood pressure, dyslipidaemia, and type 2 diabetes showed a trend toward an improved DRR of secukinumab. Furthermore, the presence of obesity did not influence the DRR of secukinumab. Different dosages, previous bDMARDs, and concomitant therapy with csDMARDs did not influence the DRR of secukinumab.
CONCLUSIONS:
A cumulative 60-month DRR of secukinumab of 57.0% in patients with PsA was retrieved. The presence of cardiometabolic multimorbidity could be associated with an improved DRR of secukinumab, whereas obesity did not affect this feature in our cohort. Previous bDMARDs, concomitant csDMARDs, and different drug dosages could not influence the DRR of secukinumab over time.

DOI: https://doi.org/10.55563/clinexprheumatol/tpp63h

Rheumatology Article